Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | BRD1 | O95696 | 1/20 | 0.47 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.47 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20233035 | 0.85 | RAB9A (0.51) | ALDH1A1RAB9AMAPTHTTNPC1 | |
| SCHEMBL1707296 | 0.84 | ALDH1A1 (0.58) | ALDH1A1MAPTHTTMEN1KMT2A | |
| SCHEMBL978780 | 0.84 | ALDH1A1 (0.58) | ALDH1A1MAPTHTTMEN1KMT2A | |
| SCHEMBL26813752 | 0.84 | HSD17B10 (0.58) | ALDH1A1RAB9AMAPTHTTNPC1 | |
| SCHEMBL19113190 | 0.82 | RAB9A (0.58) | ALDH1A1RAB9AMAPTHTTNPC1 | |
| SCHEMBL12674490 | 0.79 | ALDH1A1 (0.55) | ALDH1A1MAPTHTTMEN1KMT2A | |
| SCHEMBL979436 | 0.76 | ALDH1A1 (0.62) | ALDH1A1RAB9AMAPTHTTNPC1 | |
| SCHEMBL978793 | 0.76 | ALDH1A1 (0.61) | ALDH1A1MAPTHTTMEN1KMT2A | |
| SCHEMBL3771751 | 0.72 | RAB9A (0.74) | ALDH1A1RAB9AMAPTHTTNPC1 | |
| SCHEMBL7850067 | 0.72 | RAB9A (0.62) | ALDH1A1RAB9AMAPTHTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373974-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-9636345-B2 | Benzimidazole derivatives useful TRPM8 channel modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-02 | — | — | US | disclosed |
| US-20150150882-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL TRPM8 CHANNEL MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-04 | — | — | US | disclosed |
| US-8981113-B2 | Benzimidazole derivatives useful as TRPM8 channel modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-17 | — | — | US | disclosed |
| US-20130245085-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-19 | — | — | US | disclosed |
| EP-2440295-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-24 | — | — | EP | disclosed |
| EP-2440294-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-24 | — | — | EP | disclosed |
| US-8450497-B2 | Benzimidazole derivatives useful as TRPM8 channel modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-28 | — | — | US | disclosed |
| US-8242157-B2 | Benzimidazole derivatives useful as TRPM8 channel modulators | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-14 | — | — | US | disclosed |
| EP-2440294-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2012-04-18 | — | — | EP | disclosed |
| EP-2440295-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2012-04-18 | — | — | EP | disclosed |
| US-20110003801-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-06 | — | — | US | disclosed |
| US-20110003800-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-06 | — | — | US | disclosed |
| WO-2010144680-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010144679-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003800-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | TRPM8, TRPM4, TRPM6 | ALDH1A1 1798/4885RAB9A 765/4885MAPT 3328/4885 |
| US-20230373974-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | ALDH1A1 3575/4885RAB9A 2049/4885MAPT 4871/4885 |
| US-20130245085-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | TRPM8, TRPM4, TRPM6 | ALDH1A1 1798/4885RAB9A 765/4885MAPT 3328/4885 |
| US-20150150882-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL TRPM8 CHANNEL MODULATORS | TRPM8, TRPM4, TRPM6 | ALDH1A1 2178/4885RAB9A 651/4885MAPT 3210/4885 |
| US-20110003801-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | TRPM8, TRPM4, TRPM6 | ALDH1A1 1798/4885RAB9A 765/4885MAPT 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.